Jan 03, 2023
Decreased risk of Alzheimer disease in bladder cancer patients with intravesical Bacillus Calmette-Guérin therapy: An exploratory meta-analysis
- Junjie Tian1,
- Jianguo Gao2,
- Xiaoyi Chen1,
- Baiye Jin1
- 1Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University;
- 2Department of Urology, The First Affiliated Hospital of Huzhou Normal College
Protocol Citation: Junjie Tian, Jianguo Gao, Xiaoyi Chen, Baiye Jin 2023. Decreased risk of Alzheimer disease in bladder cancer patients with intravesical Bacillus Calmette-Guérin therapy: An exploratory meta-analysis. protocols.io https://dx.doi.org/10.17504/protocols.io.3byl4jz12lo5/v1
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: January 03, 2023
Last Modified: January 03, 2023
Protocol Integer ID: 74665
Keywords: ad incidence in bladder cancer patient, ad risk among bladder cancer patient, bladder cancer patients with intravesical bacillus calmette, risk of alzheimer disease, bladder cancer patient, efficacy of bcg, alzheimer disease, analysis alzheimer disease, chronic progressive dementia, influence of bcg use, primary cause of chronic progressive dementia, bcg treatment, dementia, several retrospective observational cohort study, cognitive decline in various animal model, cognitive decline, efficacy, future with the aging, bcg use
Funders Acknowledgements:
the Key Project of Science and Technology Program of Zhejiang Province
Grant ID: 2020C03026
Abstract
Alzheimer disease (AD) is the primary cause of chronic progressive dementia worldwide, accounting for about 60-80% of all cases of dementia. It is a progressive neurodegenerative disorder affecting 50 million people around the world, and the number will continue to increase in future with the aging of the population. The public health burden arising from AD is expected to increase dramatically in the coming decades according to demographic trends.
Recently, accumulating experiments showed that BCG treatment could prevent, delay, and even reverse cognitive decline in various animal models for AD. To date, several retrospective observational cohort studies have reported the influence of BCG use or not on AD incidence in bladder cancer patients, but with controversial results. So far, the efficacy of BCG on the risk of AD in bladder cancer patients has not been systematically evaluated yet. Hence, our current exploratory meta-analysis aimed at investigating the efficacy of BCG in reducing AD risk among bladder cancer patients, though the relatively limited number of high-quality studies are available.
Troubleshooting
Study protocol.doc